Virax Biolabs Group Limited
Price Action
Technical Summary
DOWNTRENDVirax Biolabs Group Limited is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 8), showing significant lag compared to the market leaders. Earnings growth of 45% provides fundamental context to the price action. Investors should exercise caution due to high volatility (183% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.46 | -24.86% | BELOW |
| 50 SMA | $4.39 | -23.76% | BELOW |
| 100 SMA | $4.64 | -27.85% | BELOW |
| 150 SMA | $6.28 | -46.68% | BELOW |
| 200 SMA | $8.39 | -60.07% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VRAX in an uptrend right now?
VRAX has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.
Is VRAX overbought or oversold?
VRAX's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.
Is VRAX outperforming the market?
VRAX has a Relative Strength (RS) Rating of 8 out of 99. VRAX is currently lagging the broader market.
Where is VRAX in its 52-week range?
VRAX is trading at $3.35, which is 12% of its 52-week high ($28.50) and 11% above its 52-week low ($0.26).
How volatile is VRAX?
VRAX has a Beta of 1.98 and 52-week volatility of 183%. It's more volatile than the S&P 500 - expect bigger swings.